Japanese chemical company, Asahi Kasei has recently relocated its Asahi Kasei Europe R&D Centre, originally sited at Chempark Dormagen, to Düsseldorf Harbour, Germany. By uniting European sales, marketing and R&D activities, the Japanese technology company further enhances its business approach towards the European automotive industry.
The new R&D lab space will also house the various materials, such as engineering plastics, synthetic rubber, as well as for battery and coating materials.
On a related development, its US-headquartered subsidiary, Zoll Medical Corporation has acquired Respicardia, a US medical equipment company, which manufactures and sells the remed System, an implantable neurostimulator device for the treatment of central sleep apnea (CSA).
The acquisition is in line with Zoll’s aim to further expand in the field of acute critical care including peripheral areas such as heart failure and respiratory dysfunction. Respicardia develops innovative therapies for conditions with large unmet clinical needs.